Evidence mapPaperPMID 27709613Full record

ArticleClinical pharmacology and therapeutics2017

Quantitative Systems Pharmacology: A Case for Disease Models.

C J Musante, S Ramanujan, B J Schmidt, O G Ghobrial, J Lu, A C Heatherington

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Editor's note on the themed issue: assessing QSP models and amplifying their impact.Journal of pharmacokinetics and pharmacodynamics · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

C J MusantePfizer Inc, Cambridge, Massachusetts, USA.
S RamanujanGenentech, South San Francisco, California, USA.
B J SchmidtBristol-Myers Squibb, Princeton, New Jersey, USA.
O G GhobrialNo institutional affiliation at the time of this research.
J LuAstraZeneca, Cambridge, UK.
A C HeatheringtonPfizer Inc, Cambridge, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantitative systems pharmacology (QSP) has emerged as an innovative approach in model-informed drug discovery and development, supporting program decisions from exploratory research through late-stage clinical trials. In this commentary, we discuss the unique value of disease-scale "platform" QSP models that are amenable to reuse and repurposing to support diverse clinical decisions in ways distinct from other pharmacometrics strategies.

Indexed as

Drug DesignModels, BiologicalBiomedical ResearchClinical Trials as TopicDecision MakingDrug DiscoveryHumansPharmacology, ClinicalSystems Biology

Identifiers

PMID27709613
PMCPMC5217891

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.